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Essentials 
 
 The role of omega-3 fatty acids (n-3 FAs) in recurrent venous thromboembolism (VTE) 
is unknown. 
 Association of n-3 FAs with recurrent VTE or total mortality was investigated in 826 
patients. 
 Whole blood n-3 FAs were inversely correlated with recurrent VTE or total mortality.  
 Major and non-major bleeding was not increased in patients with higher levels of n-3 
FAs.  
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Summary 
 
Background: The role of omega-3 fatty acids (n-3 FAs) in recurrent venous 
thromboembolism (VTE) remains unknown. 
 
Objectives: To investigated the association of n-3 FAs with recurrent VTE or total mortality 
at six months and three years. 
 
Methods: N-3 FAs were assessed in 826 patients aged ≥65 years, categorized into low, 
medium, and high based on the 25th and 75th percentile. Mean follow up was 29 months. 
 
Results: At six months, subjects with medium (adjusted hazard ratio [HR], 0.37; 95% 
confidence interval [CI], 0.22 to 0.62) and high n-3 FA levels (adjusted HR, 0.36; 95% CI, 
0.20 to 0.67) were less likely to develop recurrent VTE or total mortality, compared with low 
n-3 FAs. At three years, medium levels (adjusted HR, 0.67; 95% CI, 0.47 to 0.96) were 
associated with lower risk of recurrent VTE or total mortality. As compared with low n-3 FAs, 
the adjusted subhazard ratio [SHR] of recurrent VTE was 0.39 (95% CI, 0.15 to 0.99) in 
patients with medium and 0.17 (95% CI, 0.03 to 0.82) in patients with high n-3 FAs. The 
cumulative incidence of recurrent VTE was lower in the medium and high n-3 FA groups as 
compared with low n-3 FAs, but seems to have worn off after 3 years. Incidence of major 
and non-major bleeding was not greater in the high n-3 FA groups. 
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Conclusion: Higher levels of n-3 FA were associated with a lower risk of recurrent VTE or 
total mortality in elderly patients with VTE, but not with greater bleeding risk. 
 
Key words Bleeding, deep vein thrombosis, omega-3 fatty acids, pulmonary embolism, 
recurrent venous thromboembolism 
 
Introduction 
Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and 
pulmonary embolism (PE), remains a major cause of cardiovascular mortality [1]. The 
annual incidence is 108 per 100,000 person-years in the US [1], and incidence rates 
increase exponentially with age for both DVT and PE [1, 2]. More patients present with DVT 
than PE, but the latter accounts for the majority of VTE-related deaths [3]. VTE is considered 
to be a chronic, recurrent disease, and despite anticoagulant and thrombolytic therapy [4, 5], 
roughly one third of patients experience recurrent VTE within ten years [1], peaking at six 
months after the index VTE [2]. Importantly, the mortality risk remains increased up to 30 
years after index VTE [6]. Therefore, recurrent VTE is responsible for substantial 
comorbidities and healthcare costs [7], and identifying strategies to reduce the burden of 
recurrent VTE is crucial. 
Omega-3 fatty acids (n-3 FAs), including long-chain, marine-derived eicosapentaenoic acid 
(EPA, 20:5 n-3), docosahexaenoic acid (DHA, 22:6 n-3), docosapentaenoic acid (DPA), and 
the short-chain, plant-derived alpha-linolenic acid (ALA, 18:3 n-3), have been shown to 
prevent thrombotic events, cardiovascular disease and mortality in experimental [8-10] and 
clinical studies [11-14]. We found that treatment of mice with ALA reduces atherosclerosis 
[10] and arterial thrombosis [9] via anti-inflammatory [10], antiplatelet [8] and anticoagulant 
[9] mechanisms; similar properties have been described for long-chain marine-derived n-3 
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FAs [15]. Inflammation, coagulation, and platelet activation are the hallmarks of VTE and 
VTE-related death. Indeed, clinical studies have found an inverse association of fish or n-3 
FA intake with incident VTE [16, 17]. However, the association of n-3 FAs with VTE 
recurrence and mortality remains unclear. 
Elderly patients with prior VTE are at high risk for recurrent VTE due to their advanced age 
and frequent pro-inflammatory and pro-thrombotic comorbidities, such as cancer, 
cerebrovascular disease, immobility, hypertension, and heart failure [18, 19]. Experimental 
studies have suggested an important involvement of tissue factor-bearing microparticles [20, 
21] and inflammatory mediators such as neutrophil extracellular traps [22-24] and P-selectin 
[25, 26] in the pathogenesis of venous thrombosis. Correspondingly, these mediators have 
been linked to VTE in clinical studies [24, 27, 28]. Furthermore, platelets play a fundamental 
role in venous thrombus formation [26]. N-3 FAs have been shown to exert antiplatelet and 
anticoagulant properties by reducing platelet activation [8], vascular tissue factor activity [9], 
levels of plasma tissue factor [29], and P-selectin [29], indicating a potential implication of n-
3 FA in preventing venous thrombosis. 
In the present study, we investigate the association of whole blood n-3 FAs with recurrent 
VTE or total mortality and major and non-major bleeding in a prospective multicenter cohort 
study of elderly patients with acute VTE. 
 
Materials and Methods 
Study population 
The study was conducted as part of the Swiss Cohort of Elderly Patients with Venous 
Thromboembolism (SWITCO65+; ClinicalTrials.gov Identifier: NCT00973596), a prospective 
multicenter cohort study designed to assess short- and long-term medical outcomes in 
elderly patients with acute VTE [18]. Patients were screened at all five university and four 
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high-volume non-university hospitals in Switzerland from September 2009 to March 2012 
(n=1863). Patients aged ≥ 65 years with objectively confirmed acute, symptomatic VTE 
(proximal and/or distal DVT and/or PE) were included in the study [18]. Symptomatic DVT 
was defined as an acute onset of leg pain or swelling and incomplete compressibility of a 
venous segment on ultrasonography or an intraluminal filling defect on contrast venography 
[18]. Additional diagnostic criteria for iliac and caval DVT also included abnormal duplex flow 
patterns compatible with thrombosis or an intraluminal filling defect on spiral computed 
tomography or magnetic resonance imaging venography [18]. Symptomatic PE was defined 
as a positive spiral computed tomography or pulmonary angiography, a high-probability 
ventilation-perfusion scan, or proximal DVT documented by compression ultrasonography or 
contrast venography in patients with acute chest pain, new or worsening dyspnea, 
hemoptysis, or syncope [18]. Exclusion criteria were inability to provide informed consent, 
conditions incompatible with follow-up, language barriers, thrombosis at a different site than 
lower limb, catheter-related thrombosis, or previous enrolment in the cohort [18]. 
After exclusion of 860 patients (398, no consent; 285, inability to provide consent, 192, 
follow up not possible; 21, other site than lower limb; 7, catheter-related thrombosis; 51, 
language barriers; multiple reasons for exclusion may apply), 1003 patients were enrolled 
and 177 patients were excluded from the current study (8, patients denying use of data; 4, 
early withdrawals; 165, no bio samples available); finally, n-3 FAs were analyzed in 826 
patients.  The ethics committee of every participating center approved the study, and eligible 
patients provided informed consent.  
 
Baseline data collection and follow-up  
At baseline, study nurses prospectively collected demographic information (age and 
gender), comorbid conditions, laboratory findings, VTE-related treatment before and after 
the event, and concomitant antiplatelet therapy using standardized data collection forms. 
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Follow-up contact included one telephone interview and two face-to-face evaluations during 
the first year followed by semi-annual contacts and periodic reviews of the patient’s hospital 
chart. During each contact, study nurses interviewed patients to obtain information about the 
date and type of clinical events (recurrent VTE, mortality). In case of an event, this 
information was complemented by reviewing medical charts and interviewing patients’ 
primary care physicians and family members. Patients were followed up at a mean of 29 
months. 
 
Blood sampling and whole blood fatty acid composition 
At the baseline visit EDTA-anticoagulated blood was drawn after minimal venostasis; 
aliquots of samples were cryovialed in 3 ml polypropylene tubes and temporarily stored at -
80°C at each participating centre before they were transported to and stored at the 
SWITCO65+ biobank at the Central Laboratory of Hematology of Lausanne University 
hospital, Switzerland. For whole-blood fatty acid (EPA + DHA + DPA + ALA) determination, 
samples were shipped on dry ice to Omegametrix GmbH, Planegg, Germany (no prior 
freeze-thaw cycles). Whole-blood composition was analysed according to the HS-Omega-3 
Index® methodology as previously described [30]. Fatty acid methyl esters were generated 
from whole blood by acid transesterification and analyzed by gas chromatography using a 
GC2010 Gas Chromatograph (Shimadzu, Duisburg, Germany) equipped with a SP2560, 
100-m column (Supelco, Bellefonte, PA) hydrogen as carrier gas. Fatty acids were identified 
by comparison with a standard mixture of fatty acids characteristic of erythrocytes. Results 
are given as fatty acids expressed as a percentage of total identified fatty acids after 
response factor correction. The coefficient of variation for fatty acid levels was 5%. Analyses 
were quality controlled according to DIN ISO 15189. Samples were labelled with individual 
8-digit European article number barcodes and sent to Omegametrix for n-3 FA 
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determination. Subsequently, bar codes with corresponding fatty acid contents were 
provided to the statistician. All researchers involved in fatty acid determination were blinded. 
 
End points 
Our primary endpoint was recurrent VTE or total mortality. Recurrent VTE during follow-up 
was defined as new fatal or new non-fatal PE, or new DVT (proximal and/or distal) [18]. 
Diagnosis of recurrent VTE during follow-up was established with the following criteria: for 
DVT, abnormal results on ultrasonography; for PE, CT, or angiography, showing new 
intraluminal defects or ventilation-perfusion lung scan showing a high-probability pattern with 
new perfusion defects. A new proximal DVT, associated with new PE symptom(s) (shortness 
of breath, chest pain, syncope) was also considered as recurrent PE [18]. 
Our secondary endpoints included recurrent VTE, total mortality, and major or non-major 
bleeding. Major bleeding was defined as a fatal bleeding, symptomatic bleeding in a critical 
organ (intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, pericardial, or 
intramuscular with compartment syndrome), bleeding with a reduction of haemoglobin ≥20 
g/L, or bleeding leading to the transfusion ≥2 units of packed red blood cells [18]. Non-major 
bleeding was defined as bleeds that did not fulfill the criteria for major bleeding but required 
medical attention [18]. 
Statistical analysis 
We categorized n-3 FA into low, medium, and high levels based on pre-specified cut-offs, 
the 25th and 75th percentile (low, 2.7 – 4.9%; medium, 4.9 – 6.6%; high, 6.6 – 11.6%). 
Cumulative incidences of recurrent VTE or total mortality and bleeding were estimated by 
the Kaplan-Meier method, and survivor functions between groups were compared using the 
logrank test. Associations between n-3 FA levels and the time to a first VTE recurrence, or a 
first major or non-major bleeding were assessed by competing risk regression accounting for 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
death as a competing event, according to Fine and Gray’s method [31]. The method yields 
subhazard ratios (SHR) with corresponding 95% confidence intervals (CI) and p-values for 
the event of primary interest. For total mortality and the composite of VTE recurrence or total 
mortality, an ordinary Cox regression was calculated with robust standard errors. We 
adjusted the models for risk factors that had previously been shown to be associated with 
VTE recurrence, total mortality, and bleeding. Recurrent VTE or total mortality was adjusted 
for age, gender, overt PE, cancer, heart failure, chronic lung disease, body mass index, 
provoked VTE, prior VTE, and periods of anticoagulation as a time-varying covariate. 
Bleeding was adjusted for age, cancer, history of major bleeding, overt PE, antiplatelet 
therapy, and periods of anticoagulation as a time-varying covariate. VTE recurrence was 
adjusted for age, gender, body mass index, cancer, provoked VTE, prior VTE, and periods 
of anticoagulation as a time-varying covariate. Total mortality was adjusted for age, gender, 
overt PE, cancer, immobilization, heart failure, chronic lung disease, and periods of 
anticoagulation as a time-varying covariate. Missing values in covariates used for 
adjustment were rare (<1%) and thus assumed to be absent. In addition, we performed a 
sensitivity analysis excluding cancer patients (n=678) as cancer is associated with a higher 
incidence of VTE [1], and there is evidence that higher intake of n3 FAs is associated with a 
lower incidence and progression of cancer [32]. All analyses were performed using Stata 13 
(Stata Corporation, College Station, Texas). Reported STROBE guidelines have been the 
basis for reporting our results [33].  
Results 
Study population 
Patients had a mean age of 75 years, and 46 % were female. Patients’ baseline 
characteristics were comparable across n-3 FA categories. Exceptions were a lower 
prevalence of arterial hypertension in the high n-3 FA group, a higher prevalence of cancer 
in the low n-3 FA group, and differences in the type of initial anticoagulation (Table 1).  
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Recurrent VTE or total mortality after six months 
After 6 months, the cumulative incidence of the primary endpoint, recurrent VTE or total 
mortality, was inversely associated with levels of n-3 FA (low, 18.1%; medium, 7.7%; high, 
7.3%) (Fig. 1A). After adjustment, patients with high (HR, 0.36; 95% CI, 0.20 to 0.67) and 
medium (HR, 0.37; 95% CI, 0.22 to 0.62) n-3 FA levels were less likely to develop recurrent 
VTE or total mortality than patients with low levels (Table 2). Similarly, the individual 
secondary end points, recurrent VTE alone (low, 5.8%; medium, 2.3%; high, 1.0%) and total 
mortality alone (low, 16.7%; medium, 5.9%; high, 6.3%) occurred less frequently in patients 
with medium and high n-3 FA levels (Fig. 1B). After adjustment, medium (SHR, 0.39; 95% 
CI, 0.15 to 0.99) and high levels (SHR, 0.17; 95% CI, 0.03 to 0.82) were associated with a 
lower incidence of recurrent VTE, compared to low levels (Table 2). Medium (SHR, 0.29; 
95% CI, 0.16 to 0.51) and high n-3 FA levels (SHR, 0.34; 95% CI, 0.17 to 0.68) were also 
associated with a lower risk of total mortality (Table 2). At 6 months, a total of 71 deaths 
were observed: 31 deaths (43.7%) were attributable to cancer, 17 (23.9%) to PE (4 [5.6%] 
PE-related, 13 [18.3%] possibly PE-related), 4 (5.6%) to bleeding, 4 (5.6%) to sepsis, 4 
(5.6%) to pulmonary causes other than PE, 3 (4.2%) to infection, 1 (1.4%) to acute coronary 
syndrome, 1 (1.4%) to left ventricular failure, 2 (2.8%) to others, and 4 (5.6%) to unknown 
causes. 
 
Recurrent VTE or total mortality after three years 
At 3 years, the cumulative incidence of the primary endpoint differed between n-3 FA levels 
(low, 35.7%; medium, 27.1%; high, 32.9%). Medium levels (HR 0.67; 95% CI, 0.47 to 0.96) 
were associated with a lower risk of recurrent VTE or total mortality than low n-3 FA levels 
(Table 2 and Fig. 3A). The occurrence rate of the secondary endpoint, recurrent VTE, was 
comparable between the groups after three years (low, 15.1%; medium, 13.7%; high, 
16.7%) (Table 2 and Fig. 3B). However, incidence of total mortality differed among the 
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groups (low, 28.5%; medium, 18.9%; high, 20.8%) (Table 2). Medium (HR, 0.55; 95% CI, 
0.37 to 0.82) and high n-3 FAs (HR, 0.67; 95% CI, 0.42 to 1.06) were associated with a 
decreased risk of total mortality at three years, although the latter did not reach statistical 
significance (Table 2). At 3 years, a total of 165 deaths were observed: 59 deaths (35.8%) 
were attributable to cancer, 30 (18.1%) to PE (7 [4.2%] PE-related, 23 [13.9%] possibly PE-
related), 13 (7.9%) to sepsis, 12 (7.3%) to infection, 11 (6.7%) to bleeding, 9 (5.5%) to left 
ventricular failure, 6 (3.6%) to pulmonary causes other than PE, 3 (1.8%) to acute coronary 
syndrome, 2 (1.2%) to stroke, 2 (1.2%) to suicide, 5 (3.0%) to others, and 13 (7.9%) to 
unknown causes. 
 
Bleeding after six months and three years 
The cumulative incidence of major or non-major bleeding was different across n-3 FA 
categories at six months (low, 20.4%; medium, 12.5%; high, 16.0%) (Fig. 2, Table 2), 
interestingly with the highest bleeding rates in patients with low n-3 FA levels; however, the 
differences did not reach statistical significance. After adjustment, patients with medium 
levels (SHR 0.64; 95% CI, 0.41 to 0.98) but not patients with high n-3 FA levels (SHR 0.82; 
95% CI, 0.51 to 1.32) had a reduced risk of bleeding compared to patients with low levels 
(Table 2 and Fig. 2), suggesting a potential benefit of medium n-3 FA levels in terms of 
short-term bleeding risk. At three years, the cumulative incidence of bleeding did not differ 
between n-3 FA categories (low, 32.3%; medium, 34.5%; high, 32.9%) (Table 2 and Fig. 4).  
 
Kaplan-Meier curves suggest a non-linear rather than a linear relationship between n-3 FAs 
and outcomes. Nevertheless, we performed analyses using n-3 FAs as a continuous 
measure, and found a consistent pattern of results for all endpoints similar to categorical 
analyses (Supplementary Table 1). 
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Sensitivity analysis of patients without cancer 
The prevalence of active cancer differed significantly across n-3 FA groups and was higher 
in patients with low n-3 FAs. Furthermore, cancer was a major cause of total mortality both 
at six months and three years. To investigate the association of n-3 FAs with recurrent VTE 
or total mortality and bleeding independently of cancer, we performed a sensitivity analysis 
excluding active cancer patients. Baseline characteristics were comparable, with the 
exceptions of arterial hypertension and type of initial anticoagulation (Supplementary Table 
2). Similar to the primary analysis, recurrent VTE occurred less frequently in patients with 
high (SHR 0.17; 95% CI, 0.03 to 0.94) and medium (SHR 0.33; 95% CI, 0.12 to 0.95), 
compared with low n-3 FA levels after 6 months. Moreover, higher n-3 FAs were not 
associated with higher bleeding rates (Supplementary Table 3). Patients with medium and 
high n-3 FA levels were less likely to develop the primary endpoint recurrent VTE or total 
mortality as well as the secondary endpoint total mortality; however, this associations did not 
reach statistical significance (Supplementary Table 3). At 3 years, n-3 FAs in patients 
without active cancer were not associated with recurrent VTE, total mortality, or bleeding 
(Supplementary Table 3). 
 
Discussion 
This prospective multicenter cohort study investigated the association of total whole blood n-
3 FAs with recurrent VTE or total mortality and with major and non-major bleeding in elderly 
patients with acute VTE. In this study, n-3 FAs were inversely associated with the cumulative 
incidence of recurrent VTE or total mortality. At six months, patients with higher n-3 FA 
levels had a risk reduction of more than 60% for developing recurrent VTE or total mortality. 
Importantly, the individual secondary endpoints, recurrent VTE, and total mortality, occurred 
significantly less frequently in patients with medium and high compared to low n-3 FA levels. 
At three years, only medium n-3 FAs were associated with a significant risk reduction of 33% 
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for developing recurrent VTE or total mortality. Importantly and consistently, medium and 
high levels of n-3 FAs were not associated with greater bleeding rates at either six months or 
three years. Since a reduced incidence of cancer has been reported in patients with higher 
intake of n-3 FAs and cancer contributed substantially to total mortality in the current study, 
we undertook a sensitivity analysis excluding patients with active cancer. This still revealed a 
substantial and clinically relevant risk reduction of 67% and 83% for developing recurrent 
VTE after six months in patients with medium and high n-3 FAs, respectively at six months. 
The association of n-3 FAs or fish intake with VTE has previously been examined in 
epidemiological studies and provided inconsistent results. Some studies have reported no 
association of fish or n-3 FAs with incident VTE [34-36] whereas others have found a weak 
correlation of fish consumption with the reduction of provoked VTE [17]. Steffen et al. 
reported a lower incidence of VTE associated with higher quintiles of fish consumption and 
n-3 FAs and suggested a threshold pattern effect rather than a linear trend [16]. These 
studies have assessed fish and n-3 FA intake by food frequency questionnaires, which have 
recently been shown to be hampered by up to 50% of participants providing implausible data 
[37]. In addition, n-3 FA uptake is not only affected by intake but also by absorption, food 
interaction, genetics, and catabolism, among others [38]. Thus, determining whole blood n-3 
FA content by gas chromatography, an analytical procedure with low variability [38], reflects 
patients’ n-3 FA status more reliably and appropriately. 
We and others have found plausible mechanisms in experimental studies by which n-3 FAs 
may prevent venous thrombosis including anti-inflammatory, antiplatelet and anticoagulant 
properties [8, 9, 39]. Recently, we have reported that ALA did not prevent acute venous 
thrombosis in mice in a model of vena cava stenosis or in a model of photochemical-induced 
venous endothelial injury [40]. Consistent with these results, long-chain n-3 FAs did not 
prevent venous thrombosis in a model of stasis and hypercoagulability [41], whereas others 
have demonstrated beneficial effects of the long-chain n-3 FA EPA [39]. These inconsistent 
results in rodents may be difficult to translate to the human situation, especially to elderly 
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patients with multiple risk factors, a setting which cannot be modeled in animals. On the 
other hand, differences in pathophysiology may explain the apparent discrepancy. The 
animal models consist of an acute and short-term injury with a relatively short exposure to n-
3 FAs, whereas low-dose and long-term protective mechanisms of n-3 FAs may apply in 
elderly patients with proinflammatory and prothrombotic backgrounds. Age is a main risk 
factor for VTE [1] and is also associated with other risk factors for VTE such as 
hypertension, heart failure, cancer, and stroke [18]. Studies have demonstrated that n-3 FAs 
reduce blood pressure [11] and heart failure [42], and n-3 FA were associated with a 
reduction of some cancer types [32]. This suggests that the substantial reduction of 
recurrent VTE or total mortality observed in this study may in part be due to additional non-
coagulation-related protective effects of n-3 FAs. 
Bleeding occurred significantly less frequently in the medium group and tended to be so in 
the high n-3 FA group (Table 2) after six months. In line with this observation, a recent study 
reported no association of high n-3 FA levels with bleeding rates in patients with acute 
myocardial infarction and antithrombotic therapy [43]. Also, randomized clinical trials did not 
report increased bleeding rates in patients treated with n-3 FAs [44, 45], and a recent meta-
analysis found no association between n-3 FAs and hemorrhagic strokes [46]. The findings 
that high n-3 FA levels are associated with a lower incidence of recurrent VTE, but not with 
higher bleeding rates, appear attractive for potential future applications. In addition, given 
that patients with low n-3 FAs are not at risk for major bleeding, they may be good 
candidates for receiving prolonged anticoagulant therapy. 
Patients in the current prospective cohort study were recruited from September 2009 to 
March 2012, and were followed for a mean of 29 months. Thus, our data reflect recent 
clinical practice. The overall proportion of the primary endpoint was 10.0% and 28.0% at six 
months and three years, respectively. The 6-month incidence rate of VTE recurrence was 
5.8 (95% CI, 3.8 to 8.7) per 100 patient-years. Incidence rates were similar to previous 
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studies reporting 7% within 6 months [47], 7.7% within the first year [48] and 11.1 (95% CI, 
10.5–11.8) per 100 patient years within 6 months [2].  
Limitations of the current study include the absence of novel oral anticoagulants, which were 
not approved for clinical use during the study period; which this could have affected the 
primary endpoint and interfered with the beneficial association of medium and high n-3 FA 
levels with VTE or total mortality. Further, the number of events of some endpoints, 
particularly of recurrent VTE after 6 months with 22 events is low, which may decrease 
power. Nevertheless, significant associations, in line with our hypothesis were observed. 
Likewise, only few event rates and broad confidence intervals were found in the sensitivity 
analysis resulting in low power. However, the data is supportive of our findings, considering 
the significantly lower event rates of recurrent VTE in patients with higher n-3 FA levels and 
furthermore, the coherent trend of lower recurrent VTE and/or mortality in patients with 
higher n-3 FA levels. The current observational study found associations of n-3 FAs with 
recurrent VTE and mortality; however, a causal relationship may be investigated in 
intervention trials. The current study was performed in patients above 65 years of age; 
therefore, the findings cannot be extrapolated to the general population. In line with previous 
reports [11, 32], confounding variables were observed, including cancer and hypertension. 
Despite extensive adjustment, we cannot exclude the possibility that the association 
between n-3 FA levels and outcomes may be due to residual confounding. 
In conclusion, in elderly patients with acute VTE, medium and high levels of total whole 
blood n-3 FAs were associated with a lower risk of recurrent VTE or total mortality, but not 
with higher bleeding rates at six months. After three years, patients with medium n-3 FAs 
levels were less likely to develop recurrent VTE or total mortality. Although the current 
observational study suggests potential protective effects of n-3 FAs on recurrent VTE and 
total mortality, the efficacy of preventing recurrent VTE or total mortality by n-3 FA 
supplementation remains to be investigated in interventional trials.  
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Addendum 
M. F. Reiner designed the study, analyzed and interpreted the data, wrote the manuscript 
and approved the final version. A. Limacher designed the study, analyzed and interpreted 
the data, wrote the manuscript and approved the final version. S. Stivala interpreted the 
data, contributed to the discussion and approved the final version. N. R. Bonetti interpreted 
the data, contributed to the discussion and approved the final version. M. Méan designed the 
study, interpreted the data, wrote the manuscript and approved the final version. M. Egloff 
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Figure Titles and Legends 
Figure 1. Kaplan–Meier Estimates of Time to Recurrent VTE or Total Mortality by n-3 
FA levels up to 6 Months. 
A) At 6 months, the cumulative incidence of recurrent VTE or total mortality differed among 
levels of n-3 FA (low, 18.1%; medium, 7.7%; high, 7.3%). After adjustment, patients with 
medium (hazard ratio [HR], 0.37; 95% confidence interval [CI], 0.22 to 0.62) and high n-3 FA 
levels (HR, 0.36; 95% CI, 0.20 to 0.67) had a lower risk of recurrent VTE or total mortality. 
B) Also, cumulative incidence of recurrent VTE differed among n-3 FA levels (low, 5.8 %; 
medium, 2.3%; high, 1.0%). After adjustment, patients with medium (subhazard ratio [SHR], 
0.39; 95% CI, 0.15 to 0.99) and high n-3 FA levels (SHR, 0.17; 95% CI, 0.03 to 0.82) had a 
lower risk of recurrent VTE. 
 
Figure 2. Kaplan–Meier Estimates of Time to Major or Non-Major Bleeding by n-3 FA 
levels up to 6 Months. 
After 6 months, major and non-major bleeding occurred less often in patients with medium 
and high levels of total n-3 FA, however, differences were not significant (low, 20.4%; 
medium, 12.5%; high, 16.0%). After adjustment, patients with medium (subhazard ratio 
[SHR], 0.64; 95% confidence interval [CI], 0.41 to 0.98), but not high levels (SHR, 0.82; 95% 
CI 0.51 to 1.32) had fewer bleeding events. 
Figure 3. Kaplan–Meier Estimates of Time to Recurrent VTE or Total Mortality by n-3 
FA levels up to 3 Years. 
A) At 3 years, the cumulative incidence of recurrent VTE or total mortality differed among 
levels of n-3 FAs (low, 35.7%; medium, 27.1%; high, 32.9%). After adjustment, patients with 
medium levels (hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.47 to 0.96), but not 
patients with high levels of n-3 FAs (HR, 0.88; 95% CI, 0.60 to 1.30) had a lower risk for 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
recurrent VTE or total mortality. B) At 3 years, cumulative incidence of recurrent VTE 
differed among n-3 FA levels (low, 15.1%; medium, 13.7%; high, 16.7%). After adjustment, 
patients with medium (subhazard ratio [SHR], 0.90; 95% CI, 0.54 to 1.52) and high n-3 FA 
levels (SHR, 1.13; 95% CI, 0.63 to 2.01) had a lower risk of recurrent VTE. 
 
Figure 4. Kaplan–Meier Estimates of Time to Major or Non-Major Bleeding by n-3 FA 
levels up to 3 Years. 
Cumulative incidences of major and non-major bleeding did not differ significantly between 
n-3 FA groups (low, 32.3%; medium, 34.5%; high, 32.9%). 
 
Tables 
 
Table 1. Baseline characteristics by n-3 FA levels. 
 All Low 
n-3 FA 
Medium 
n-3 FA 
High 
n-3 FA 
 n (%) or median 
(IQ-range) 
n (%) or median 
(IQ-range) 
n (%) or median 
(IQ-range) 
n (%) or median 
(IQ-range) 
Total N N = 826 N = 207 N = 412 N = 207 
Age 75.0 
(69.0; 81.0) 
75.0 
(69.0; 79.0) 
75.0 
(69.0; 82.0) 
75.0 
(70.0; 82.0) 
Gender (female) 376 (46%) 96 (46%) 188 (46%) 92 (44%) 
Body mass index 26.4 
(24.0;  29.8) 
26.3 
(23.5;  29.8) 
26.8 
(24.2;  30.0) 
25.8 
(23.8;  29.4) 
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Overt PE 579 (70%) 145 (70%) 284 (69%) 150 (72%) 
Prior VTE 240 (29%) 71 (34%) 111 (27%) 58 (28%) 
Major surgery during 
the last 3 months 
120 (15%) 33 (16%) 64 (16%) 23 (11%) 
Current oestrogen 
therapy during the last 
3 months 
27 (3%) 5 (2%) 15 (4%) 7 (3%) 
Immobilization during 
the last 3 months 
180 (22%) 42 (20%) 92 (22%) 46 (22%) 
Provoked index VTE 241 (29%) 59 (29%) 126 (31%) 56 (27%) 
Active cancer 148 (18%) 50 (24%) 68 (17%) 30 (14%) 
History of major 
bleeding 
81 (10%) 15 (7%) 38 (9%) 28 (14%) 
Arterial hypertension 531 (64%) 136 (66%) 279 (68%) 116 (56%) 
Chronic or acute heart 
failure 
100 (12%) 24 (12%) 55 (13%) 21 (10%) 
Treated atrial 
fibrillation 
11 (1%) 5 (2%) 5 (1%) 1 (0%) 
Diabetes mellitus 127 (15%) 39 (19%) 64 (16%) 24 (12%) 
Cerebrovascular 
disease (stroke, TIA) 
80 (10%) 20 (10%) 37  (9%) 23 (11%) 
Chronic lung disease 117 (14%) 29 (14%) 55 (13%) 33 (16%) 
Chronic renal disease 149 (18%) 46 (22%) 73 (18%) 30 (14%) 
Anemia 315 (38%) 92 (44%) 149 (36%) 74 (36%) 
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Platelet count <150 G/l 122 (15%) 32 (15%) 59 (14%) 31 (15%) 
Creatinine >107 umol/l 182 (22%) 55 (27%) 84 (20%) 43 (21%) 
Aspirin 228 (28%) 59 (29%) 119 (29%) 50 (24%) 
Concomitant 
antiplatelet therapy 
257 (31%) 66 (32%) 136 (33%) 55 (27%) 
Polypharmacy 426 (52%) 116 (56%) 212 (51%) 98 (47%) 
Anticoagulation prior 
to index VTE 
42 (5%) 16 (8%) 18 (4%) 8 (4%) 
Type of initial parenteral 
anticoagulation 
    
  Low molecular 
  weight heparin 
411 (50%) 107 (52%) 213 (52%) 91 (44%) 
  Unfractionated 
  heparin 
244 (30%) 72 (35%) 111 (27%) 61 (29%) 
  Fondaparinux 142 (17%) 26 (13%) 69 (17%) 47 (23%) 
  Danaparoid 1 (0%) 0 (0%) 1 (0%) 0 (0%) 
  None 28 (3%) 2 (1%) 18 (4%) 8 (4%) 
Initial vitamin K 
antagonist therapy 
714 (86%) 166 (80%) 363 (88%) 185 (89%) 
 
Values were missing in body mass index (1%), anaemia (6%), platelet count (6%), and creatinine (7%). Provoked 
VTE was defined as presence of ≥1 of the following factors: major surgery, oestrogen therapy, or immobilization 
during the last 3 months; polypharmacy was defined as prescription of more than four different drugs. IQ = 
interquartile, n-3 FA = omega-3 fatty acids; PE = pulmonary embolism, TIA = transient ischemic attack, VTE = 
venous thromboembolism.  
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Table 2. Association of n-3 FA levels with clinical endpoints at 6 months and 3 years. 
 
 Level N° events/ 
patient-years 
IR per 100 patient-
years (95% CI) 
Crude SHR or HR 
(95% CI) 
Adjusted SHR or HR 
(95%-CI) 
Clinical Endpoints at 6 Months 
VTE recurrence 
or death 
Low 37 / 90.0 41.1 (29.8 to 56.8) 1 (reference) 1 (reference) 
Medium 31 / 194.2 16.0 (11.2 to 22.7) 0.39 (0.24 to 0.63) 0.37 (0.22 to 0.62) 
High 15 / 98.3 15.3 (9.2 to 25.3) 0.37 (0.21 to 0.68) 0.36 (0.20 to 0.67) 
VTE recurrence Low 11 / 90.0 12.2 (6.8 to 22.1) 1 (reference) 1 (reference) 
Medium 9 / 194.2 4.6 (2.4 to 8.9) 0.40 (0.17 to 0.97) 0.39 (0.15 to 0.99) 
High 2 / 98.3 2.0 (0.5 to 8.1) 0.18 (0.04 to 0.79) 0.17 (0.03 to 0.82) 
Overall mortality Low 34 / 90.8 37.4 (26.8 to 52.4) 1 (reference) 1 (reference 
Medium 24 / 195.6 12.3 (8.2 to 18.3) 0.33 (0.20 to 0.56) 0.29 (0.16 to 0.51) 
High 13 / 98.7 13.2 (7.7 to 22.7) 0.36 (0.19 to 0.67) 0.34 (0.17 to 0.68) 
Any bleeding Low 39 / 83.5 46.7 (34.1 to 63.9) 1 (reference) 1 (reference) 
Medium 50 / 180.0 27.8 (21.1 to 36.6) 0.63 (0.42 to 0.96) 0.64 (0.41 to 0.98) 
High 32 / 91.7 34.9 (24.7 to 49.3) 0.80 (0.50 to 1.26) 0.82 (0.51 to 1.32) 
Clinical Endpoints at 3 Years 
VTE recurrence 
or death 
Low 68 / 390.7 17.4 (13.7 to 22.1) 1 (reference) 1 (reference) 
Medium 100 / 908.8 11.0 (9.0 to 13.4) 0.65 (0.47 to 0.88) 0.67 (0.47 to 0.96) 
High 63 / 439.7 14.3 (11.2 to 18.3) 0.83 (0.59 to 1.18) 0.88 (0.60 to 1.30) 
VTE recurrence Low 24 / 390.7 6.1 (4.1 to 9.2) 1 (reference) 1 (reference) 
Medium 45 / 908.8 5.0 (3.7 to 6.6) 0.90 (0.55 to 1.48) 0.90 (0.54 to 1.52) 
High 28 / 439.7 6.4 (4.4 to 9.2) 1.11 (0.64 to 1.93) 1.13 (0.63 to 2.01) 
Overall mortality Low 55 / 411.3 13.4 (10.3 to 17.4) 1 (reference) 1 (reference) 
Medium 70 / 952.4 7.3 (5.8 to 9.3) 0.57 (0.40 to 0.81) 0.55 (0.37 to 0.82) 
High 40 / 473.2 8.5 (6.2 to 11.5) 0.65 (0.43 to 0.98) 0.67 (0.42 to 1.06) 
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Any bleeding Low 57 / 345.0 16.5 (12.7 to 21.4) 1 (reference) 1 (reference) 
Medium 120 / 784.2 15.3 (12.8 to 18.3) 1.01 (0.74 to 1.39) 1.00 (0.72 to 1.38) 
High 60 / 399.8 15.0 (11.7 to 19.3) 1.00 (0.69 to 1.44) 1.00 (0.69 to 1.44) 
 
Recurrent VTE or total mortality was adjusted for age, gender, overt PE, cancer, heart failure, chronic lung 
disease, BMI, provoked VTE, prior VTE, and periods of anticoagulation as a time-varying covariate. Bleeding was 
adjusted for age, cancer, history of major bleeding, overt PE, antiplatelet therapy, and periods of anticoagulation 
as a time-varying covariate. VTE recurrence was adjusted for age, gender, BMI, cancer, provoked VTE, prior 
VTE, and periods of anticoagulation as a time-varying covariate. Total mortality was adjusted for age, gender, 
overt PE, cancer, immobilization, heart failure, chronic lung disease, and periods of anticoagulation as a time-
varying covariate. HR = hazard ratio, IR = incidence rate, n-3 FA = omega-3 fatty acids, SHR = subhazard ratio, 
VTE = venous thromboembolism. 
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